The collaboration sees Bristol-Myers Squibb making an investment in LSP 5, the latest LSP fund with a representative joining the LSP 5 Advisory Board.
The two companies will work together in order to identify European disrupting technologies and products in immuno-oncology and other areas of unmet medical need.
Bristol-Myers Squibb is widely acknowledged to be one of the leaders in Immuno-oncology and is also pursuing potential treatment options in other areas of significant unmet need, including cardiovascular diseases such as heart failure and thrombosis, certain genetically defined diseases, fibrosis and immunoscience.
LSP (Life Sciences Partners) is one of Europe’s largest and most experienced specialist life-science investors providing financing for private and public life-science companies. It has over €1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston.